Introduction
============

Smoking is associated with considerable mortality and morbidity.[@b1-ceor-10-067] Smoking accounts for \>5 million premature deaths worldwide each year,[@b2-ceor-10-067] including \>480,000 in the US alone.[@b3-ceor-10-067],[@b4-ceor-10-067] It also causes a wide range of chronic diseases and cancers, which place a considerable burden on health care systems.[@b1-ceor-10-067]

Strategies for smoking cessation are important for reducing the overall smoking burden[@b4-ceor-10-067] and have proved to be effective.[@b5-ceor-10-067] Between 2005 and 2014, the prevalence of cigarette smoking among US adults decreased from 20.9% to 16.8%.[@b3-ceor-10-067] Smokers' interest in quitting smoking is high: in 2015, 68.0% of current US adult daily smokers reported that they wanted to stop smoking,[@b6-ceor-10-067] and an estimated 55.4% of all smokers had attempted to quit during the past year.[@b6-ceor-10-067]

The current clinical practice guidelines recommend that a combination of medication and counseling is most effective for obtaining cessation.[@b4-ceor-10-067],[@b5-ceor-10-067],[@b7-ceor-10-067] Smoking cessation medications include nicotine replacement therapy (NRT), available both over the counter and on prescription depending on formulation, and bupropion (Zyban®; GlaxoSmithKline plc, London, UK) and varenicline (Champix®; Pfizer, Inc., New York, NY, USA), both available by prescription only.

The Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES), the largest clinical trial of smoking cessation pharmacotherapies to date, adopted a double-blind, triple-dummy design to compare the efficacy and neuropsychiatric safety profile of varenicline, bupropion, NRT patch, and placebo in smokers with and without psychiatric disorders.[@b8-ceor-10-067] The study, conducted at 140 centers in 16 countries between 2011 and 2015, comprised a 12-week treatment phase and a 12-week follow-up period.[@b8-ceor-10-067] Study participants were randomized to treatment, with stratification into nonpsychiatric and psychiatric cohorts. The primary efficacy end point was continuous smoking abstinence for Weeks 9--12, and a secondary efficacy end point was continuous abstinence for Weeks 9--24.[@b8-ceor-10-067] Study results indicated that, for these primary and secondary end points, varenicline was more effective than bupropion, NRT patch, and placebo, and bupropion and NRT patch were more effective than placebo.[@b8-ceor-10-067]

The cost-effectiveness of smoking cessation interventions has been previously shown in several studies.[@b5-ceor-10-067],[@b9-ceor-10-067]--[@b12-ceor-10-067] Varenicline, specifically, has been shown to be cost-effective in the US health care setting using the Benefits of Smoking Cessation on Outcomes (BENESCO) model, a Markov model developed to simulate the lifetime direct costs and consequences of a single quit attempt in a hypothetical cohort of US adult smokers.[@b13-ceor-10-067] In light of the new comparative efficacy data from the EAGLES trial and the decreasing prevalence of smoking in the US population, the objective of this study was to update the inputs of the BENESCO model to investigate long-term health and economic outcomes of smoking cessation treatment using varenicline, bupropion, NRT patch, and placebo.

Methods
=======

The BENESCO model
-----------------

The BENESCO model was initially developed to assess the cost-effectiveness of a single smoking cessation attempt in a hypothetical cohort of US adult smokers using varenicline, bupropion, NRT, or unaided cessation.[@b13-ceor-10-067] Designed as a Markov model, the impact of a single attempt in the first year on the incidence of smoking-related mortality and morbidity is estimated in 1-year cycles running up to a lifetime, which is set at 99 years of age, after which subjects remaining in the model will die in the next cycle due to all-cause mortality.[@b13-ceor-10-067] This requirement ensures that all patients in the model will experience mortality through the duration of the simulation. Never and former smokers are excluded from the simulation because the initial cohort focuses on current smokers attempting to quit.[@b13-ceor-10-067]

The model includes health states corresponding to chronic obstructive lung disease (COPD), lung cancer, coronary heart disease (CHD), and stroke, in order to simulate the epidemiological pattern of the most prevalent and costly of the smoking-related conditions.[@b13-ceor-10-067] The transition probabilities of subjects between these health states are derived from three factors: 1) smoking status, including initial quit rate and subsequent short- or long-term relapse rates; 2) morbidity status, derived from the relative risk of developing one of the four smoking-related morbidities; and 3) risk of mortality.[@b13-ceor-10-067] At the conclusion of each cycle, subjects stay in the same state, undergo transition to another morbidity state, or die from one of the included morbidities or another cause (all-cause mortality).

In the present study, prevalence, incidence, mortality, direct treatment costs of smoking-related conditions, and the efficacy and costs of the smoking cessation interventions have been updated based on the current literature. Smoking-related disease health utilities and risks of these diseases relative to nonsmokers were assumed to remain unchanged over time, as previously reported.[@b14-ceor-10-067] The BENESCO model takes the perspective of the US health care system.

BENESCO model updates
---------------------

Several data updates were included in this analysis to modernize our study from the initial cost-effectiveness analyses published by Howard et al.[@b13-ceor-10-067] The efficacy estimates used in the BENESCO model were updated to reflect comparative head-to-head data arising from the EAGLES trial.[@b8-ceor-10-067] However, these efficacy estimates required adjustments for use within the BENESCO framework for two reasons: 1) the EAGLES trial provided efficacy end points separately for the psychiatric and nonpsychiatric populations, whereas the BENESCO model does not differentiate between the two populations, and 2) the EAGLES trial measured continuous abstinence from Week 9 to Week 24, whereas the BENESCO model uses a 52-week cycle.

The first adjustment to derive the quit rates used in the model addressed the subpopulation distribution. The EAGLES trial comprised two cohorts stratified by psychiatric history: 4,000 subjects with and 4,000 without a history of psychiatric disorders. Subjects with a history of psychiatric disorders were defined as having at least one of the following Axis I or II diagnoses: psychotic disorders (schizophrenia and schizoaffective disorder), mood disorders (major depression and bipolar I and II disorders), anxiety disorders (panic disorder with or without agoraphobia), posttraumatic stress disorder, obsessive-compulsive disorder, social phobia, generalized anxiety disorder, and a past history of borderline personality disorder. Due to the equal sampling between the two cohorts, subjects with psychiatric history were over represented in the EAGLES trial.

Therefore, to obtain a single quit rate which represents the distribution of psychiatric comorbidities in the general population, a literature search was conducted, and a study reporting that 29.2% of the general population was diagnosed with these conditions was identified.[@b15-ceor-10-067] For each treatment group, the Weeks 9--24 efficacy end points from the two cohorts were pooled using a weighted average to obtain a single Weeks 9--24 quit rate representative of the distribution of psychiatric disorders in the general population ([Table 1](#t1-ceor-10-067){ref-type="table"}). After pooling, the Weeks 9--24 continuous abstinence rates for each treatment group were again adjusted to approximate a 1-year quit rate by applying the weighted average of the ratios of the Week 52 and Week 24 quit rates for varenicline, bupropion, and placebo from an analysis by Nides et al.[@b16-ceor-10-067] Thus, the effectiveness of a single quit attempt for each treatment ultimately used in this study was calculated based on the Weeks 9--24 end points from EAGLES,[@b8-ceor-10-067] pooled with data about the prevalence of psychiatric disorders in the general population,[@b15-ceor-10-067] and extended to 52 weeks using the average abstinence ratio.[@b16-ceor-10-067] The quit rates used in this updated model are shown in [Table 1](#t1-ceor-10-067){ref-type="table"}.

Additional updates to the data inputs, as previously mentioned, focused on providing newer data for the epidemiology of smoking in the US population, the epidemiology and direct treatment costs of the four smoking-related conditions included in the model, and the costs of the smoking cessation interventions. The US population figures and all-cause mortality rates were identified from the US Census Bureau.[@b17-ceor-10-067],[@b18-ceor-10-067] The demographic breakdown of smokers included in the study cohort was estimated from Centers for Disease Control and Prevention (CDC) reports ([Table 2](#t2-ceor-10-067){ref-type="table"}): Current Cigarette Smoking Among Adults in the US[@b3-ceor-10-067] and Summary Health Statistics for US Adults.[@b19-ceor-10-067] Prevalence, incidence, and mortality rates of COPD,[@b20-ceor-10-067],[@b21-ceor-10-067] lung cancer,[@b17-ceor-10-067],[@b22-ceor-10-067] CHD,[@b20-ceor-10-067],[@b23-ceor-10-067] and stroke[@b17-ceor-10-067],[@b18-ceor-10-067],[@b20-ceor-10-067],[@b23-ceor-10-067]--[@b25-ceor-10-067] were identified through literature searches that included reports from the American Heart Association, the CDC, and peer-reviewed publications.

Disease management and intervention costs were updated for each smoking-related disease and were inflated as necessary to reflect 2014 US costs by applying Medical Care Consumer Price Indexes ([Table 3](#t3-ceor-10-067){ref-type="table"}).[@b26-ceor-10-067]--[@b29-ceor-10-067] The treatment costs of varenicline, bupropion, and NRT patch were defined based on the average Wholesale Acquisition Cost unit price sourced from the First DataBank's FDB MedKnowledge data, as of June 1, 2014, and the recommended course for smoking cessation.[@b30-ceor-10-067]

Updated model data analysis
---------------------------

After updating the BENESCO inputs as described earlier, the model was run for an entry population of 18,394,068 smokers to compare varenicline, bupropion, NRT patch, and placebo with regard to the incidence of smoking-related morbidity, the incidence of smoking-related mortality, and cost-effectiveness with a time horizon from 2 years to lifetime. A default discount rate of 3% was used for costs and outcomes. The lifetime horizon was regarded as capturing all the costs and benefits resulting from smoking and smoking cessation. A probabilistic sensitivity analysis (PSA) was conducted with 1,000 iterations at the lifetime time horizon for each pair-wise comparison of smoking cessation strategies, resulting in cost-effectiveness acceptability curves and cost-effectiveness planes.

Results
=======

The updated BENESCO model showed that, as expected, the cumulative incidence of COPD, lung cancer, CHD, and stroke at the lifetime horizon varied according to treatment efficacy, with varenicline having the lowest cumulative incidence of these conditions and placebo having the highest ([Table 4](#t4-ceor-10-067){ref-type="table"}). For varenicline, there were an estimated 319,730 fewer smoking-related morbidities over the lifetime compared with placebo. Compared with bupropion and NRT, use of varenicline resulted in 175,998 and 166,156 fewer smoking-related morbidities over the lifetime, respectively ([Table 4](#t4-ceor-10-067){ref-type="table"}). A similar trend was observed at other time horizons.

Similarly, the cumulative incidence of smoking-related deaths from these conditions recorded at each time horizon was also lowest with varenicline and highest with placebo ([Table 5](#t5-ceor-10-067){ref-type="table"}). At a lifetime horizon, smoking-related mortality rates decreased by 198,240 patients with varenicline compared with placebo (bupropion, 109,123; NRT patch, 103,021). Compared with bupropion and NRT patch, treatment with varenicline resulted in 89,117 and 95,219 fewer deaths, respectively.

Annual treatment-related costs were higher for varenicline than for the other comparators at the time horizons of 2, 5, and 10 years ([Table 6](#t6-ceor-10-067){ref-type="table"}). At these time horizons, varenicline, bupropion, and NRT patch were all more expensive than placebo. At the 20-year horizon, treatment-related costs were lower for varenicline than for NRT patch. At the lifetime horizon, total costs (including costs of interventions and smoking-related conditions) were lower for varenicline than for bupropion or NRT patch, and both varenicline and bupropion had considerably lower total costs than NRT patch and placebo. At all time horizons, quality-adjusted life years (QALYs) gained was greatest for varenicline, followed by bupropion, NRT patch, and placebo ([Table 6](#t6-ceor-10-067){ref-type="table"}). As a result of these data, at the lifetime horizon, varenicline dominated all comparator strategies, being more effective and less costly overall, while bupropion dominated NRT patch and placebo, and NRT patch dominated placebo ([Table 7](#t7-ceor-10-067){ref-type="table"}).

For each pairwise treatment comparison, a PSA based on 1,000 simulations resulted in the median estimated incremental cost-effectiveness ratio (ICER) changing by \<0.1% for each additional simulation, indicating that the aggregate results were stable. From the PSAs conducted for varenicline versus each comparator at the lifetime horizon, greatest uncertainty in cost-effectiveness was observed for varenicline versus bupropion and varenicline versus NRT patch (data not shown). In all pairwise treatment comparisons, both costs and QALYs were consistently in favor of varenicline across the majority of PSA iterations. As a result, the probability of varenicline being a cost-effective strategy compared to placebo and NRT approached 100% and compared to bupropion 85% beyond the \$10,000/QALY threshold.

Discussion
==========

The aim of this study was to undertake an updated cost-effectiveness analysis, using current epidemiology inputs and recently published smoking cessation data from the EAGLES trial.

The results of this present cost-effectiveness analysis indicate that smoking cessation provides good value for money. Compared with bupropion or NRT patch, varenicline, the most efficacious pharmacotherapy, appears to prevent the greatest number of cases of smoking-related disease and death while providing a long-term economic benefit. The results demonstrate that varenicline is dominant, ie, less costly and more effective, at the lifetime horizon vs bupropion, NRT, and placebo. These cost-effectiveness results are comparable with the results originally published by Howard et al[@b13-ceor-10-067] 10 years earlier.

The population estimates reflecting the proportion of US adult smokers who make an attempt to quit reflect the trend toward a decreased smoking prevalence in the US in the past few years, as well as the changed prevalence of smoking-related disease.[@b3-ceor-10-067] Based on the lifetime results, the number needed to treat (NNT) to prevent one smoking-related death was estimated to be 93 for varenicline, 169 for bupropion, and 179 for NRT patch. Similarly, the NNT to prevent one case of smoking-related morbidity was estimated to be 58 for varenicline, 105 for bupropion, and 111 for NRT patch.

A key strength of this study is that it is the first to present cost-effectiveness analyses of all three smoking cessation treatments using data obtained from EAGLES, the largest head-to-head study of varenicline, bupropion, and NRT patch. Additionally, the data inputs were updated to reflect the changing landscape of smoker demographics and epidemiology of smoking-related disease over the past decade. Finally, the study population was more representative of the general population with the inclusion of patients having a psychiatric history, in comparison with the study population from previous clinical trials in which these patients were excluded by design.

A limitation of this study is that pooling was required to consolidate the efficacy values of the two subpopulations for each intervention. Unfortunately, there was no identified published study of the distribution of psychiatric diagnoses in the current smoker population, and thus, prevalence of psychiatric diagnoses in the general population was used. While the magnitude of the prevalence of psychiatric diagnosis in the general population may be debated, a recently published meta-analysis was used.[@b15-ceor-10-067] Furthermore, the model also had to project efficacy to 52 weeks from the 24-week data that were available. Since relapse after quitting is essentially independent of the method of quitting, a ratio of the 24- and 52-week data weighted from the Nides et al[@b16-ceor-10-067] study provided a reasonable 6-month relapse rate. Additionally, the study design utilized in the Nides et al[@b16-ceor-10-067] study was comparable with the EAGLES study design and included three of the four EAGLES treatment arms (varenicline, bupropion, and placebo).

Additional limitations inherent in the methodology included the absence of indirect costs, such as lost productivity, the effects of each pharmacotherapy on the costs of other treatments, and the potential increased costs of health care for former smokers over their assumed longer life span versus smokers. Furthermore, the model structure captures only four disease states and allows for only one morbidity at any given cycle, which is an over simplification of the true clinical impact of smoking. However, this assumption is conservative, and likely the economic results are therefore an underestimate of the true impact of smoking cessation. An area of future research would be in further refining the efficacy of smoking cessation and associated cost implications by age groups to understand the implications of smoking cessation across different age ranges and in conducting a study on the impact of retreatment with varenicline following an unsuccessful first attempt in the US setting.

Conclusion
==========

This study, an update to the original varenicline cost-effectiveness study published by Howard et al,^31^ demonstrated consistency in the findings that a single quit attempt with varenicline is less costly and more effective than other smoking cessation pharmacotherapies at the lifetime despite changing smoker demographics, epidemiology of smoking-related disease, and varying costs over the past decade.
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###### 

Derived abstinence (efficacy) rates for interventions used in BENESCO

  Intervention   Abstinence rate (%)                 
  -------------- --------------------- ------ ------ ------
  Varenicline    18.3                  25.5   23.4   17.9
  Bupropion      13.7                  18.8   17.3   13.3
  NRT patch      13.0                  18.5   16.9   13.0
  Placebo        8.3                   10.5   9.9    7.6

**Notes:**

Continuous abstinence rates for Weeks 9--24 from the EAGLES trial.[@b8-ceor-10-067]

Weighted average using the global prevalence of relevant psychiatric disorders, 29.2%.[@b15-ceor-10-067] For example, for varenicline (25.5 × 0.708 + 18.3 × 0.292) = 23.4.

Using a mean Week 24-to-Week 52 correction ratio of 0.767 from Nides et al.[@b16-ceor-10-067]

**Abbreviations:** BENESCO, Benefits of Smoking Cessation on Outcomes; EAGLES, Evaluating Adverse Events in a Global Smoking Cessation Study; NRT, nicotine replacement therapy.

###### 

2014 US population figures and smoking prevalences by age and sex used in the BENESCO model[@b1-ceor-10-067],[@b3-ceor-10-067],[@b9-ceor-10-067]

  Sex and age band (years)   Population size   Smoking prevalence (%)   Smokers (n)   No. of making quit attempt
  -------------------------- ----------------- ------------------------ ------------- ----------------------------
  Males                                                                               
   18--34                    37,658,932        22.6                     8,510,919     3,634,162
   35--64                    60,671,100        21.9                     13,286,971    5,673,537
   65+                       19,599,941        10.6                     2,077,594     887,133
  Females                                                                             
   18--34                    36,444,679        16.3                     5,940,483     2,536,586
   35--64                    62,865,553        18.1                     11,378,665    4,858,690
   65+                       25,104,133        7.5                      1,882,810     803,960
  Total                      242,344,338                                43,077,442    18,394,068

**Abbreviation:** BENESCO, Benefits of Smoking Cessation on Outcomes.

###### 

Cost inputs included in the model

  Category                         Annual cost, 2014 \$US
  -------------------------------- ------------------------------------------------
  Direct treatment cost            
   COPD[@b26-ceor-10-067]          20,224
   Lung cancer[@b29-ceor-10-067]   70,110
   CHD[@b27-ceor-10-067]           10,303
   Stroke[@b28-ceor-10-067]        27,422
  Drug cost                        
   Varenicline[@b30-ceor-10-067]   843[a](#tfn6-ceor-10-067){ref-type="table-fn"}
   Bupropion[@b30-ceor-10-067]     325[a](#tfn6-ceor-10-067){ref-type="table-fn"}
   NRT patch[@b30-ceor-10-067]     602[a](#tfn6-ceor-10-067){ref-type="table-fn"}
   Placebo                         0[b](#tfn7-ceor-10-067){ref-type="table-fn"}

**Notes:**

Based on an 84-day course of treatment.

The cost of placebo was set at zero.

**Abbreviations:** CHD, chronic heart disease; COPD, chronic obstructive pulmonary disease; NRT, nicotine replacement therapy.

###### 

Cumulative incidence of smoking-related morbidities for varenicline versus other treatments estimated using the BENESCO model

  Morbidity      Model year   Lifetime                           
  -------------- ------------ ---------- ----------- ----------- -----------
  Varenicline                                                    
   COPD          35,048       104,875    247,302     628,021     1,696,165
   Lung cancer   56,560       167,696    407,405     1,049,365   2,861,506
   CHD           63,205       170,952    378,044     842,332     1,735,185
   Stroke        36,084       101,808    239,546     564,833     1,253,474
   Total         190,897      545,331    1,272,296   3,084,551   7,546,331
  Bupropion                                                      
   COPD          35,282       105,838    253,208     645,606     1,738,141
   Lung cancer   57,424       171,379    419,700     1,082,096   2,937,579
   CHD           63,817       173,226    384,200     854,904     1,751,300
   Stroke        36,547       103,591    243,753     573,038     1,263,043
   Total         193,070      554,034    1,300,861   3,155,643   7,690,063
  NRT                                                            
   COPD          35,298       105,904    253,612     646,810     1,741,015
   Lung cancer   57,483       171,632    420,542     1,084,337   2,942,788
   CHD           63,859       173,382    384,622     855,764     1,752,403
   Stroke        36,579       103,713    244,041     573,600     1,263,699
   Total         193,219      554,630    1,302,817   3,160,511   7,699,905
  Placebo                                                        
   COPD          35,569       107,016    260,440     667,138     1,789,539
   Lung cancer   58,482       175,889    434,755     1,122,174   3,030,730
   CHD           64,566       176,012    391,738     870,297     1,771,031
   Stroke        37,114       105,775    248,904     583,085     1,274,761
   Total         195,732      564,692    1,335,838   3,242,694   7,866,061

**Abbreviations:** BENESCO, Benefits of Smoking Cessation on Outcomes; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; NRT, nicotine replacement therapy.

###### 

Incidence of smoking-related mortality at different time horizons

  Intervention   Mortality (number of patients)                                   
  -------------- -------------------------------- --------- --------- ----------- -----------
  Varenicline    147,511                          359,159   751,621   1,735,578   4,497,529
  Bupropion      147,798                          362,212   763,431   1,771,001   4,586,646
  NRT patch      147,818                          362,421   764,239   1,773,427   4,592,748
  Placebo        148,150                          365,951   777,891   1,814,376   4,695,769

**Abbreviation:** NRT, nicotine replacement therapy.

###### 

Treatment-related costs (\$US) and quality-adjusted life years gained

  Intervention          Time horizon, years                                 
  --------------------- --------------------- --------- --------- --------- -----------
  Varenicline                                                               
   Cost (\$ millions)   107,064               225,029   382,508   640,647   1,011,025
   QALYs (1000s)        29,743                69,591    124,114   198,134   269,694
  Bupropion                                                                 
   Cost (\$ millions)   97,608                215,950   374,630   636,110   1,011,938
   QALYs (1000s)        29,742                69,582    124,073   197,962   269,199
  NRT patch                                                                 
   Cost (\$ millions)   102,709               221,077   379,839   641,548   1,017,749
   QALYs (1000s)        29,742                69,581    124,071   197,950   269,165
  Placebo                                                                   
   Cost (\$ millions)   91,721                210,523   370,674   636,246   1,018,747
   QALYs (1000s)        29,741                69,571    124,023   197,750   268,593

**Abbreviations:** NRT, nicotine replacement therapy; QALY, quality-adjusted life year.

###### 

Cost-effectiveness (lifetime horizon)

  Intervention   ICER (\$/QALY gained)                         
  -------------- ----------------------- ---------- ---------- ----------
  Varenicline    --                      Dominant   Dominant   Dominant
  Bupropion                              --         Dominant   Dominant
  NRT patch                                         --         Dominant

**Note:** Dominant: more effective and less costly than comparator.

**Abbreviations:** ICER, incremental cost-effectiveness ratio; NRT, nicotine replacement therapy; QALY, quality-adjusted life year.
